Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 51 to 100 of 752

TitleReference numberPublishedLast updated
Ruxolitinib for treating polycythaemia veraTA921
Daridorexant for treating long-term insomniaTA922
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTA927
Bimekizumab for treating axial spondyloarthritisTA918
Pegunigalsidase alfa for treating Fabry diseaseTA915
Bimekizumab for treating active psoriatic arthritisTA916
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiencyTA914
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathyTA913
Semaglutide for managing overweight and obesityTA875
Cipaglucosidase alfa with miglustat for treating late-onset Pompe diseaseTA912
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancerTA911
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)TA910
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancerTA909
Rimegepant for preventing migraineTA906
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapyTA908
Deucravacitinib for treating moderate to severe plaque psoriasisTA907
Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fractionTA902
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancerTA903
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancerTA904
Upadacitinib for previously treated moderately to severely active Crohn's diseaseTA905
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal)TA901
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancerTA898
Tixagevimab plus cilgavimab for preventing COVID-19TA900
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphomaTA894
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapyTA895
Bulevirtide for treating chronic hepatitis DTA896
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and overTA893
Daratumumab with bortezomib and dexamethasone for previously treated multiple myelomaTA897
Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal)TA899
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemiaTA891
Mosunetuzumab for treating relapsed or refractory follicular lymphomaTA892
Risankizumab for previously treated moderately to severely active Crohn's diseaseTA888
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)TA889
Difelikefalin for treating pruritus in people having haemodialysisTA890
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapyTA886
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancerTA887
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatmentsTA881
Voclosporin with mycophenolate mofetil for treating lupus nephritisTA882
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphomaTA883
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)TA884
Tezepelumab for treating severe asthmaTA880
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)TA879
Finerenone for treating chronic kidney disease in type 2 diabetesTA877
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancerTA876
Eptinezumab for preventing migraineTA871
Cannabidiol for treating seizures caused by tuberous sclerosis complexTA873
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphomaTA874
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapiesTA872
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myelomaTA870
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)TA867

Results per page

  1. 10
  2. 25
  3. 50
  4. All